Skip to main content
Premium Trial:

Request an Annual Quote

Boehringer Ingelheim Expands License for Spotfire s DecisionSite

NEW YORK, Sept. 27 (GenomeWeb News) - Spotfire said today that Boehringer Ingelheim will deploy its DecisionSite software worldwide across its R&D activities.

 

The agreement extends a narrower licensing agreement that Boehringer Ingelheim has had with Spotfire since 1997 to use the software in genomics, lead discovery, and medicinal chemistry.

 

Under the global agreement, the company will deploy DecisionSite across its research organization, from target discovery through pre-clinical research, in Germany, Austria, Italy, Canada, and the United States.

 

Financial terms of the agreement were not disclosed.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.